US FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx, as companion diagnostic to aid in identifying patients with esophageal or GEJ carcinoma: Santa Clara, California Saturday, Marc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results